

MAHA BETRAYED

How RFK oversaw **\$225M**
in new dog and cat lab
spending under Trump

WHITE
COAT
WASTE



Since Robert F. Kennedy Jr. took office as HHS Secretary,
a White Coat Waste investigation has uncovered
new NIH spending on dog and cat experiments
totaling more than

\$225,000,000¹



¹ This total includes NIH awards confirmed to support dog and/or cat experiments, as well as awards identified as likely supporting such experiments based on available grant and contract descriptions and related records.



The \$225 million includes brand-new grants and contracts, additional discretionary funding for preexisting awards, and project extensions for taxpayer-funded dog and cat laboratories — new spending that began during the current Trump administration.



Secretary Kennedy promised a “dramatic reduction in animal testing” at NIH.² Nicole Kleinstreuer, NIH’s Deputy Director, also falsely claimed the spending “predates” this administration.³



New spending on dog labs includes heart-harvesting tests, force-feeding drugs to beagles, breeding puppies to become blind, and more. Over \$98 million — nearly **44% of the total identified — went to pharmaceutical companies. NIH also issued new discretionary funding to a Fauci-era lab where beagles are eaten alive by ticks.**

² <https://www.govinfo.gov/content/pkg/DCPD-202500467/pdf/DCPD-202500467.pdf>

³ <https://www.youtube.com/watch?v=8anDbugmKTQ>



NIH has also spent **\$11.7 million** in new taxpayer dollars on invasive cat experiments: brain and eye tests on kittens, severing cats' spinal cords and then forcing them to walk on treadmills, forcing felines to cough and hyperventilate through carbon dioxide-pumped ventilators, and electro-shocking their voice boxes.



The \$225 million in new spending on dog and cat experiments also exceeds NIH's highly publicized "investment" in alternatives (new approach methodologies or NAMs) by over \$75 million.⁴



Alarming, following the release of beagles from Ridgman Farms, NIH's cumulative new spending on dog and cat experiments under Secretary Kennedy spiked by approximately 50 percent — from \$150 million in June 2026 to over \$225 million by September.⁵

⁴ <https://www.nih.gov/news-events/news-releases/nih-invests-150-million-human-based-research-reduce-use-animal-models>

⁵ <https://www.whitecoatwaste.org/blog/2026/06/13/wcw-investigation-tiny-kittens-tortured-in-nih-funded-university-of-florida-lab>


TABLE OF CONTENTS



EXECUTIVE SUMMARY	02
PRECEDENT: BEAGLEGATE PROVED NIH CAN CANCEL ANIMAL EXPERIMENTS	06
TIMELINE: RFK’S RHETORIC VS. RFK’S RECEIPTS	07
THE RECEIPTS: NEW SPENDING ON DOG AND CAT EXPERIMENTS	09
A PHASE-OUT REQUIRES SPENDING CUTS, NOT NAMS	13
BRAND-NEW AWARDS UNDER RFK	14
NEW RFK MONEY, EXISTING AWARDS	19
METHODOLOGY	27
ABOUT WHITE COAT WASTE	28

PRECEDENT: BEAGLEGATE PROVED NIH CAN CANCEL ANIMAL EXPERIMENTS

In 2021, “BeagleGate” — a landmark White Coat Waste investigation — exposed National Institute of Allergy and Infectious Diseases (NIAID) spending on deadly dog experiments under Dr. Anthony Fauci. That same year, before taking office, Secretary Kennedy cited White Coat Waste in his book *The Real Anthony Fauci*⁶, specifically crediting records obtained by our organization that exposed a \$424,000 NIAID-funded experiment in which infected flies were strapped to the skin of healthy beagle puppies.



In 2022, White Coat Waste exposed another plan by NIAID to spend nearly \$2 million for hay fever experiments on six-month-old beagle puppies. White Coat Waste organized bipartisan grassroots advocacy and congressional opposition led by Senator Joni Ernst. Following that scrutiny, Dr. Fauci personally signed a letter of response to the senator — and canceled the planned experiments.

BeagleGate established an important precedent: NIH can cancel approved grants and contracts for animal experiments when it chooses to act.^{7,8}



Actual Fauci-funded
labs uncovered by
White Coat Waste



⁶ Robert F. Kennedy Jr., *The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health* (Skyhorse Publishing, 2021).

⁷ <https://www.whitecoatwaste.org/blog/2021/10/26/beaglegate-a-timeline/>

⁸ <https://www.whitecoatwaste.org/blog/2022/07/05/beaglegate-victory-nih-cancels-faucis-runny-nose-experiments-following-wcw-campaign/>

TIMELINE: RFK'S RHETORIC VS. RFK'S RECEIPTS

Beginning on Tax Day, April 15, 2025, White Coat Waste exposed continued NIH funding for dog and cat experiments under Secretary Kennedy and, once again, rallied intense grassroots and congressional pressure. On July 10, 2025 — following four million targeted ads that mobilized 243,486 phone calls and emails to Secretary Kennedy — Deputy Director Nicole Kleinstreuer appeared on the Director's Desk Podcast and announced that NIH will phase out dog and cat experiments.^{9 10}

White Coat Waste continued following the money.^{11 12} Despite that pledge, we uncovered more than \$225 million in new NIH spending on dog and cat experiments (see pages 14–26). Deputy Director Kleinstreuer and NIH officials have attempted to dismiss concerns about this spending by falsely claiming it “predates” their appointments and they are “constrained under the law” to continue funding the grants.¹³

In January 2026, White Coat Waste filed an Information Quality Act

complaint demanding that NIH correct Deputy Director Kleinstreuer's false and misleading statements; after NIH repeatedly delayed its response, White Coat Waste escalated the matter to the HHS Office of Inspector General in June.¹⁴ The following month, NIH denied the request on the baseless ground that Kleinstreuer's false statements of fact regarding the NIH's legal authority and funding activity were “personal opinion.”¹⁵ White Coat Waste's request for reconsideration of that decision is pending as of the time of publication.



I don't think we should do research on dogs or cats. Absolutely not... I understand that there's part of the extramural portfolio that exists that predates [NIH Director Jay Bhattacharya] and I. We are constrained under the law to leave those existing grants in place for now.... But to phase them out, we are working tirelessly behind the scenes.”

— NICOLE C. KLEINSTREUER, PH.D.
NIH DEPUTY DIRECTOR

9 <https://www.whitecoatwaste.org/blog/2025/07/08/nih-digs-in-on-faucis-dog-and-cat-labs-wcw-sparks-congressional-crackdown/>

10 <https://www.whitecoatwaste.org/blog/2025/07/11/white-coat-waste-forces-nih-to-phase-out-dog-and-cat-labs/>

11 <https://www.whitecoatwaste.org/blog/2026/02/05/instant-impact-rep-nancy-mace-urges-rfk-jr-to-cut-nih-funding-for-dog-and-cat-testing-cites-white-coat-waste-investigations/>

12 <https://www.whitecoatwaste.org/blog/2026/04/13/wtf-rfk-wcws-tax-week-ads-expose-rfks-funding-for-faucis-labs/>

13 <https://www.youtube.com/watch?v=8anDbugmKTQ>

14 https://aspe.hhs.gov/sites/default/files/IQA_Responses/89_FINAL_REQUEST_White_Coat_Waste,_NIH_Kleinstreuer_Information_Quality_Request_for_Correction.pdf

15 https://aspe.hhs.gov/sites/default/files/documents/21cab821d9d62a617dac6ab7cf419636/Final_Response_FR01_NIH_Response_to_Jared_Goodman.pdf

RHETORIC

WHAT THE NIH SAID

RECEIPTS

WHAT THE NIH DID

FEBRUARY 2025

RFK takes office as HHS Secretary.

APRIL 2025

RFK promises a “dramatic reduction in animal testing” at NIH.

JUNE 2025

Kleinstreuer tells NPR animal testing is “still very important” and “often scientifically justified.” Says NIH won’t phase it out “overnight.”

JULY 2025

Kleinstreuer claims the spending “predates” this Trump administration and says NIH is “working tirelessly” to phase out dog and cat testing.

SEPTEMBER 2025

NIH awards a new \$7.2 million contract to a colony that breeds dogs with severe bleeding disorders.

JULY 2025

NIH awards a \$486,110 grant (worth up to \$2.4 million) for brain experiments on cats, \$439,016 to a lab that breeds cats with glaucoma, and extends a grant supporting kitten heart-failure tests. NIH also provides \$916,400 to force-feed beagles weight-loss drugs.

JUNE 2025

NIH provides another \$598,651 to a deadly muscular dystrophy dog lab and renews the grant for five more years (Exhibit A).

EXHIBIT B:
Uncovered by
White Coat Waste.

MARCH 2026

NIH announces a \$150 million “investment” in NAMs.

JUNE 2026

White Coat Waste identifies more than \$150 million in new spending on dog and cat tests.

MAY 2026

NIH provides \$536,741 to a lab that infests beagles with ticks (Exhibit C) and \$686,054 more to a grant that supported experiments in which cats were forced to hyperventilate and had their voice boxes electrically shocked.

FEBRUARY 2026

NIH awards a new \$811,217 grant for deadly glucose experiments on dogs and another new \$444,125 grant to grow hookworms inside puppies. NIH also provides \$1.4 million more for two grants supporting invasive heart experiments on dogs.

JANUARY 2026

NIH sends \$826,381 to a lab that breeds dogs to go blind and run obstacle courses (Exhibit B).

EXHIBIT C: Photos obtained from UMC through an open records request in August 2026 show capsules containing biting ticks attached to beagles in a Fauci-era experiment.

Uncovered by
White Coat Waste.

SEPTEMBER 2026

White Coat Waste’s identified total climbs to more than \$225 million — up roughly 50% in just over two months.

This new portfolio-wide analysis shows that NIH continued making consequential funding decisions long after the current leadership took office.

As of June 2026, White Coat Waste had identified more than \$150 million in NIH spending on dog and cat experiments since Kennedy became HHS Secretary.¹⁶ By September, that figure had climbed to more than \$225 million¹⁷ — an increase of approximately 50 percent in just over two months (see pages 14–26). That increase came after the release of beagles from Ridglan Farms.

The \$225 million in new spending under Secretary Kennedy includes brand-new grants and contracts, additional discretionary funding for preexisting awards and long-running labs, project extensions that kept taxpayer-funded labs operating, and renewals of breeding colonies years into the future. It does not mean that every underlying experiment began under the current administration.

That distinction is precisely why NIH’s “predates” defense fails.

Some experiments originated under previous administrations, but NIH retained discretion over whether to award new funding, provide additional funds, renew or extend existing projects, and approve entirely new grants and contracts. The experiments may have started earlier; the new spending did not.

NIH’s more than \$225 million in new spending on dog and cat experiments also exceeds the agency’s highly publicized “investment” in alternatives (new approach methodologies or NAMs). In March 2026, NIH announced just over \$150 million for NAMs — more than \$75 million less than White Coat Waste identified in new spending on dog and cat experiments.¹⁸

The next section examines examples of individual awards behind the \$225 million total and illustrates how these portfolio-level funding decisions kept existing laboratories operating and launched new dog and cat experiments.

THE RECEIPTS: NEW SPENDING ON DOG AND CAT EXPERIMENTS



The following examples represent just a handful of the funding decisions behind the more than \$225 million spent under Secretary Kennedy.

Funding dog testing at pharmaceutical companies:

NIH has provided more than \$98 million in new funding to pharmaceutical companies¹⁹ conducting dog experiments since Secretary Kennedy took office. This accounts for approximately 44 percent of the total identified in this investigation.

Drilling holes in kitten skulls:

NIH issued a new grant worth up to \$2.4 million to the University of Minnesota (UMN) for experiments on 60 kittens as young as two months old (Exhibit D). Records obtained by White Coat Waste show that the lab drills holes into their skulls, injects viruses into their brains, intentionally induces strokes, and ultimately kills them.²⁰

¹⁶ <https://www.whitecoatwaste.org/blog/2026/06/13/wcw-investigation-tiny-kittens-tortured-in-nih-funded-university-of-florida-lab>

¹⁷ This total includes NIH awards confirmed to support dog and/or cat experiments, as well as awards identified as likely supporting such experiments based on available grant and contract descriptions and related records.

¹⁸ <https://www.nih.gov/news-events/news-releases/nih-invests-150-million-human-based-research-reduce-use-animal-models>

¹⁹ “Pharmaceutical companies” encompasses drug and biotechnology developers, contract laboratories, and biomedical research organizations engaged in drug development and testing.

²⁰ <https://www.whitecoatwaste.org/blog/2026/01/14/wcw-investigation-new-nih-grant-pays-lab-to-breed-kittens-drill-their-skulls-induce-strokes-at-the-university-of-minnesota/>

Other Information					
Opportunity Number PA-20-185		Administering Institutes or Centers National Institute of Neurological Disorders and Stroke		Project Start Date 01-August-2025	
Study Section Special Emphasis Panel [ZRG1-IBV-P(01)Q]		Assistance Listing Number 93.853		Project End Date 30-April-2030	
Fiscal Year 2026		DUNS Number 555917996		Budget Start Date 01-May-2026	
Award Notice Date 07-April-2026		UEI KABJZBBJ4B54		Budget End Date 30-April-2027	
		No Cost		Extension	

EXHIBIT D: NIH RePORTER records show that the new NIH grant for the UMN kitten lab began under RFK.

Breeding kittens to go blind:

NIH also issued a new \$439,016 grant for a University of Wisconsin-Madison colony that breeds nearly 300 kittens with glaucoma. Some kittens in this colony are killed before they are one day old so their eyes can be cut out and dissected, while others endure eye injections and repeated testing before being killed.²¹

Killing dogs in glucose experiments:

NIH provided \$3.9 million to Vanderbilt University through new and ongoing grants supporting deadly glucose experiments on dogs, including a new five-year award approved in February 2026.²²

Force-feeding weight-loss drugs to beagles:

NIH provided an additional \$916,400 to a Syntis Bio project that force-feeds experimental weight-loss drugs to beagles.²³

21 <https://www.whitecoatwaste.org/blog/2025/12/03/kittengate-bhattacharyas-nih-funds-cruel-cat-colony-despite-phase-out-pledge/>
22 <https://www.whitecoatwaste.org/blog/2026/05/05/wcw-investigation-rfks-nih-doles-out-3-9m-in-new-tax-funding-for-deadly-dog-lab-at-vanderbilt-u/>
23 <https://www.whitecoatwaste.org/blog/2025/04/15/wcw-investigation-nih-paying-billionaire-moderna-co-founder-to-torture-beagles-for-weight-loss-drug/>

IDENTIFICATION OF EACH ANIMAL BEING DELIVERED (See reverse for Breed Abbreviations)							ACQUIRED FROM		DISPOSITION		
A. TATTOO OR USDA TAG NO.	B. DOG	C. CAT	D. AGE OR DATE OF BIRTH	E. WT.	F. BREED OR TYPE (If mixed breed, list 2 dominant breeds)	G. DESCRIPTION OF ANIMAL (Color, Distinctive Marks, Hair, Tail Tattoos, etc.)	H. DATE ACQUIRED	I. NAME AND ADDRESS USDA LICENSE OR REGISTRATION NUMBER, OR DRIVER'S LICENSE NUMBER AND STATE, VEHICLE LICENSE NUMBER AND STATE.	J. Date Removed or Sold	K. Date Died or Euthanized (Specify)	
025-84	M	M	5/21/2025	11.5	Beagle	Tricolor	7/1/25	Ridgman Farms Inc P.O. Box 919 Mt. Hope, WI 53572			
025-85	M	M	5/22/25	21	Beagle	Tricolor	7/1/25				

EXHIBIT E: UMC acquisition records obtained through an open records request show that the NIH-funded lab purchased beagles from Ridgman Farms in July 2025.

Breeding dogs to go blind:

NIH provided another \$826,381 to a University of Pennsylvania lab that breeds dogs with degenerative eye disorders, injects substances into their eyes, and tests them in dark obstacle courses before many are killed and dissected.²⁴

Damaging and harvesting dogs' hearts:

NIH has provided approximately \$2 million to the University of Utah for dog experiments involving tied-off arteries, implanted pacemakers and electrodes, electric shocks, radiation damage to heart tissue, and the harvesting of dogs' hearts.²⁵

Breeding dogs to suffer from muscular and neurodegenerative diseases:

NIH approved a \$598,000 renewal for the University of Missouri-Columbia (UMC) to extend a deadly dog lab. Records and videos obtained by White Coat Waste reveal a taxpayer-funded operation in which as many as 620 dogs are bred to suffer from crippling muscular dystrophy and progressive blindness.²⁶ Acquisition records also show that the lab purchased beagles from Ridgman Farms in July 2025 (Exhibit E).

24 <https://www.whitecoatwaste.org/blog/2026/01/27/wcw-investigation-nih-wastes-46m-to-blind-dogs-at-upenn/>
25 <https://www.whitecoatwaste.org/blog/2025/11/18/wcw-investigation-nih-funds-deadly-heart-experiments-on-dogs-at-university-of-utah/>
26 <https://www.whitecoatwaste.org/blog/2025/07/18/wcw-investigation-videos-show-dogs-abused-in-labs-renewed-by-bhattacharyas-nih/>

IDENTIFICATION OF EACH ANIMAL BEING DELIVERED (See reverse for Breed Abbreviations)							ACQUIRED FROM		DISPOSITION		
A. TATTOO OR USDA TAG NO.	B. DOG "X" M or F	C. CAT "X" M or F	D. AGE OR DATE OF BIRTH	E. WT.	F. BREED OR TYPE (If mixed breed, list 2 dominant breeds)	G. DESCRIPTION OF ANIMAL (Color, Distinctive Marks, Hair, Tail Tattoos, etc.)	H. DATE ACQUIRED	I. NAME AND ADDRESS USDA LICENSE OR REGISTRATION NUMBER, OR DRIVER'S LICENSE NUMBER AND STATE, VEHICLE LICENSE NUMBER AND STATE.	J. Date Removed or Sold	K. Date Died or Euthanized (Specify)	
D26-7	X		9/14/24	8.1	Beagle	Tri-color OWT-Y tattoo	10/6/25	Ridgman Farms, Inc. P.O. Box 318 35-A-009 Mt. Morris, WI 53572			
A. TATTOO OR USDA TAG NO.	B. DOG "X" M or F	C. CAT "X" M or F	D. AGE OR DATE OF BIRTH	E. WT.	F. BREED OR TYPE (If mixed breed, list 2 dominant breeds)	G. DESCRIPTION OF ANIMAL (Color, Distinctive Marks, Hair, Tail Tattoos, etc.)	H. DATE ACQUIRED	I. NAME AND ADDRESS USDA LICENSE OR REGISTRATION NUMBER, OR DRIVER'S LICENSE NUMBER AND STATE, VEHICLE LICENSE NUMBER AND STATE.	J. Date Removed or Sold	K. Date Died or Euthanized (Specify)	
D26-52	X		12/15/24	9.5	Beagle	Tri-color 1585811 tattoo	7/16/26	Marshall BioResources 5800 Lake Street Rd. North Rose, NY 14516			

EXHIBIT F: Before-and-after UMC acquisition records obtained through an open records request show the Fauci-era beagle lab purchasing dogs from Ridgman Farms (top) and later from Marshall BioResources (bottom) under RFK.

Infesting beagles with ticks:

NIH provided approximately \$1.9 million in additional funding to a Fauci-era UMC lab conducting experiments in which ticks feast on beagles.²⁷

Records obtained by White Coat Waste show that the lab switched from purchasing beagles from disgraced dog breeder Ridgman Farms to Marshall BioResources during Secretary Kennedy’s tenure (Exhibit F).

Forcing cats to cough and shocking their voice boxes:

NIH provided an additional \$686,054 to a grant that supported experiments at UMC in which cats were forced to hyperventilate on ventilators pumping carbon dioxide, made to cough with tubes inserted into their throats, and had their voice boxes electro-shocked.²⁸

Severing cats’ spinal cords:

NIH awarded \$305,627 to Temple University for experiments that sever cats’ spinal cords and force them to walk on treadmills.²⁹

Breeding puppies to suffer from bleeding disorders:

NIH awarded a new \$7.2 million contract to a University of North Carolina-Chapel Hill dog breeding colony, extending its operations through 2029. Records obtained by White Coat Waste show that the colony intentionally breeds puppies to suffer from severe hemophilia and other bleeding disorders for use in experiments.³⁰

Growing hookworms inside beagle puppies:

NIH issued a new \$444,125 grant to George Washington University to grow hookworms inside beagle puppies for use in other experiments.³¹

Inducing heart failure in kittens:

NIH extended the end date of a grant to University of Pennsylvania involving experiments at Temple University where heart failure was induced in two-month-old kittens — within days of when Deputy Director Kleinstreuer said NIH was “working tirelessly” to phase out testing on dogs and cats (Exhibit G).³²

Recipient Information
1. Recipient Name
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
3451 WALNUT ST STE 440A
PHILADELPHIA PA 19104

Federal Award Information
11. Award Number
5R01HL133080-09

Summary Federal Award Financial Information

19. Budget Period Start Date 08/01/2024 – End Date 07/31/2025	
20. Total Amount of Federal Funds Obligated by this Action	\$640,488
20 a. Direct Cost Amount	\$498,995
20 b. Indirect Cost Amount	\$141,493
21. Authorized Carryover	
22. Offset	
23. Total Amount of Federal Funds Obligated this budget period	\$640,488
24. Total Approved Cost Sharing or Matching, where applicable	\$0
25. Total Federal and Non-Federal Approved this Budget Period	\$640,488
26. Project Period Start Date 07/01/2016 – End Date 07/31/2025	
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period	\$2,173,813

Other Information
Opportunity Number
PA-20-185
Study Section
Integrative Myocardial Physiology/Pathophysiology A Study Section [MPPA]
Fiscal Year
2024
Award Notice Date
10-July-2024

Administering Institutes or Center
National Heart Lung and Blood Institute
Assistance Listing Number
93.837
DUNS Number
042250712
UEI
GM1XX56L
Z75RRBRS

Project Start Date
01-July-2016

Project End Date
31-July-2026

Budget Start Date
01-August-2024

Budget End Date
31-July-2026

EXHIBIT G: Before-and-after records from NIH RePORTER (top) and the lab’s award notice (bottom) show that NIH extended the kitten heart-failure grant under RFK.

27 <https://www.whitecoatwaste.org/blog/2026/03/17/wcw-investigation-abusive-beagle-mill-sells-puppies-to-labs-funded-by-fauci-others/>
28 <https://blog.whitecoatwaste.org/2026/03/03/wcw-investigation-tax-funded-lab-abused-former-pets-drilled-into-cats-skulls/>
29 <https://washingtoncitypaper.com/article/781583/wtf-rfk-126-million-more-sent-to-cruel-dog-and-cat-labs/>

30 <https://www.whitecoatwaste.org/blog/2025/10/01/new-wcw-investigation-exposes-nih-colony-of-cruelty-congress-demands-answers/>
31 <https://washingtoncitypaper.com/article/781583/wtf-rfk-126-million-more-sent-to-cruel-dog-and-cat-labs/>
32 <https://www.whitecoatwaste.org/blog/2025/07/24/wcw-investigation-nih-renewed-kitten-heart-failure-tests-after-phase-out-pledge/>



Taken together, these examples show that NIH is not simply administering a static portfolio inherited from previous leadership.

Under Secretary Kennedy, the agency has approved new awards, provided additional discretionary funding to Fauci-era labs, renewed long-running programs, and extended existing dog and cat projects. The issue is not merely what it inherited, but what NIH chose to keep funding.

A PHASE-OUT REQUIRES SPENDING CUTS, NOT NAMs

NIH remains the world's largest funder of animal testing and the U.S. government's top spender on dog and cat experiments — a reality that has not changed under Secretary Kennedy, who, as of this investigation, has presided over \$225 million in new spending identified by White Coat Waste.

NIH must stop issuing new taxpayer-funded grants and contracts for dog and cat experiments and prohibit supplements, renewals, or extensions that continue existing projects. A credible phase-out requires a clear, enforce-

able deadline, measurable success metrics, and hard spending cuts — not promises to replace animal experiments with NAMs.

As this investigation demonstrates, NIH has increased spending on alternatives by at least \$150 million while simultaneously adding more than \$225 million in new spending on dog and cat experiments. Increased NAM spending, by itself, is not a phase-out. Congress and taxpayers must hold NIH leadership accountable for ensuring that its funding decisions match its public commitments.

Since the start of the Trump administration, defunding dog and cat experiments has been White Coat Waste's top priority.³³ White Coat Waste was the first to demand that the Trump administration end taxpayer-funded experimentation on cats and dogs. Until that happens, Secretary Kennedy's promised phase-out remains only rhetoric.

The solution is simple:

STOP THE **WASTE**.
STOP THE

WASTEBAGS!!!

³³ <https://www.whitecoatwaste.org/blog/2025/01/13/trump-2-0-wcws-4-point-100-day-plan-to-save-20-billion-millions-of-animals>

BRAND-NEW AWARDS UNDER RFK

—

Includes NIH funding for new dog and cat grants and contracts first awarded on or after February 13, 2025 — the date RFK became HHS Secretary.

GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	START DATE	END DATE	SPECIES	FUNDING
R01DC021830	Treatment of Vocal Fold Paralysis with Muscle Progenitor Cells	NIDCD	Washington University	3/1/2025	2/28/2030	Dog	\$1,272,345
R01HL178117	Assessing myocardial fibrosis with spin locked MRI	NHLBI	University of Utah	3/10/2025	12/31/2028	Dog	\$1,498,756
R01CA291880	Silver Telluride Nanoparticle Dual-Energy Mammography Contrast Agents For Breast Cancer Screening	NCI	University of Pennsylvania	4/1/2025	3/31/2030	Dog	\$1,216,243
UG3DA061709	IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder	NIDA	Virogrenomics Biodevelopment, Inc	5/15/2025	4/30/2027	Dog	\$6,588,030
U43AA032129	Investigational New Drug (IND)-enabling Study for a New Therapeutic for Alcohol Use Disorder (AUD)	NIAAA	Stress Therapeutics, Inc.	5/15/2025	4/30/2027	Dog	\$1,994,840
R44CA291444	VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors	NCI	Velorum Therapeutics, Inc.	6/3/2025	5/31/2027	Dog	\$2,030,638
R44CA291285	Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer	NCI	Isoprene Pharmaceuticals, Inc	6/4/2025	5/31/2027	Dog	\$2,045,044
R44NS137896	Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)	NINDS	Astrocyte Pharmaceuticals	6/12/2025	5/31/2027	Dog	\$2,999,688
R44NS141531	Development of a novel oral brain penetrant therapeutic for ALS disease	NINDS	Aquinnah Pharmaceuticals, Inc	6/15/2025	5/31/2027	Dog	\$2,998,741
UG3DA061645	Advancing a non-addictive, peripherally acting opioid analgesic as a medication strategy to prevent opioid use disorder in patients undergoing treatment for pain	NIDA	Dimerx	7/1/2025	6/30/2027	Dog	\$3,349,522
R44DE033938	Regeneration of radiation-damaged salivary glands using neurogenicstimulation of stem cells	NIDCR	Hydronovo, Inc.	7/1/2025	6/30/2027	Dog	\$1,921,467
R43AA032127	Investigational New Drug Development of Noribogaine for Alcohol Use Disorder	NIAAA	Demerx, Inc.	8/1/2025	7/31/2027	Dog	\$1,710,622
UG3DA062511	Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder	NIDA	Drug Delivery Company, LLC	8/1/2025	7/31/2027	Dog	\$5,865,000
R44AI192080	Novel Therapeutic for SLE	NIAID	BioTherapeutics, Inc	8/1/2025	1/31/2026	Dog	\$314,363
R44NS145934	FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain	NINDS	Alcamena Stem Cell Therapeutics	8/7/2025	7/31/2027	Dog	\$3,000,000

BRAND-NEW AWARDS UNDER RFK



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	START DATE	END DATE	SPECIES	FUNDING
R44TR005945	Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells	NCATS	Engage Biologics, Inc.	8/1/2025	7/31/2027	Dog	\$865,162
R01CA303975	Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore	NCI	Oregon Health & Science University	8/15/2025	7/31/2029	Dog	\$2,491,138
R44AG091987	A 13-Week Oral Gavage Toxicity Study of OLX-07010 in Beagle Dogs Followed by a 4-Week Recovery Period	NIA	Oligomerix, Inc	8/20/2025	2/29/2028	Dog	\$1,999,404
R01CA293595	Clinical Translation of a Choline-targeted NIR dye to guide lung cancer resection	NCI	University of Pennsylvania	8/18/2025	7/31/2030	Dog	\$1,297,988
R01HL173183	Neural Mechanisms of Premature Ventricular Contraction-Induced Cardiomyopathy Revealed by Targeted Neuromodulation of the Cardiac Neuraxis	NHLBI	Richmond Institute for Veterans Research	9/1/2025	5/31/2030	Dog	\$472,511
R41GM159487	Investigating the safety and efficacy of pillararene sulfates as novel and effective reversal agents for both steroidal and non-steroidal neuromuscular blocking agents.	NIGMS	Reversal Therapeutics, Inc	9/12/2025	8/31/2026	Dog	\$368,367
R44CA302180	Development of Second Generation BLVRB Inhibitors for Treating Chemotherapy Induced Thrombocytopenia	NCI	Blood Cell Technologies	9/1/2025	8/31/2026	Dog	\$400,000
R01HL178535	Epicardial high-definition electrotherapy of Afib	NHLBI	Northwestern University at Chicago	9/1/2025	6/30/2029	Dog	\$1,177,260
R03CA300928	Conditional Agonism: PD1-Dependent Activation of 4-1BB for Enhanced Safety	NCI	Auburn University	9/1/2025	8/31/2027	Dog	\$153,959
R44CA302283	Development of a novel MYC inhibitor for cancer therapy	NCI	Vortex Therapeutics, Inc.	9/12/2025	8/31/2027	Dog	\$2,244,974
R44AG090144	Development of a Drug Candidate for the Treatment of Agitation in Alzheimer's Disease	NIA	PsychoGenics	9/20/2025	9/19/2026	Dog	\$495,699
R41CA306717	The development of humanized SEMA7A-antagonist mAbs for the therapeutic treatment of breast cancer	NCI	Pearl Scientific LLC	9/18/2025	8/31/2026	Dog	\$392,695
UG3AG097136	Bone-Targeted Nanoparticles to Accelerate Fracture Healing in Aging Populations	NIA	University of Oregon	9/15/2025	8/31/2027	Dog	\$886,403
R44AG091827	AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies	NIA	Advantage Therapeutics	9/20/2025	5/31/2027	Dog	\$2,499,325

BRAND-NEW AWARDS UNDER RFK



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	START DATE	END DATE	SPECIES	FUNDING
R44CA295155	Drug development of RK-33 for breast cancer treatment	NCI	Natsar Pharmaceuticals, Inc.	9/22/2025	8/31/2027	Dog	\$1,634,811
R44NS143576	Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy	NINDS	RespireRx Pharmaceuticals, Inc.	9/23/2025	8/31/2027	Dog	\$1,499,869
75N92025D00042	NHLBI maintenance of canine models of human bleeding disorders	NHLBI	University of North Carolina Chapel Hill	9/23/2025	9/19/2029	Dog	\$7,222,977
R44EY038121	IND-enabling studies of KTX-1161, a novel NRF2 activator for corneal endothelial disease	NEI	Kuria Therapeutics, Inc.	9/30/2025	8/31/2026	Dog	\$399,865
R21AI196592	Cross-class selection for anthelmintic resistance in the hookworm Ancylostoma caninum	NIAID	George Washington University	2/3/2026	1/31/2028	Dog	\$444,125
R01DK146464	Signaling Mechanisms of Ultra-Stable and Glucose-Regulated Insulin Analogs	NIDDK	Indiana University	2/18/2026	1/31/2031	Dog	\$811,217
R01CA300732	Direct and indirect MCL1 targeting for high-efficiency therapy of lung metastasis in-vivo and on-a-chip	NCI	Oregon Health & Science University	3/26/2026	2/28/2031	Dog	\$625,179
R61AI197037	A Single Long-Acting Injection For HBV Treatment Using Novel Entecavir Prodrugs For PWLH	NIAID	Scripps Research Institute	4/1/2026	3/31/2031	Dog	\$899,741
R21CA309173	Understanding plant virus-based adjuvants as therapeutics	NCI	University of California, San Diego	4/1/2026	3/31/2028	Dog	\$420,505
R21TR005230	Exploring AAV gene therapy for Alport syndrome using a dog model	NCATS	Oregon Health & Science University	5/1/2026	4/30/2028	Dog	\$448,013
R01HL183508	Therapeutic Development of the RyR2-Inhibitor ent-Verticilide for Atrial Fibrillation	NHLBI	Vanderbilt University Medical Center	6/1/2026	2/29/2028	Dog	\$1,732,198
R01DK145079	Co-Regulation of Metabolism by Insulin-Glucagon Fusion Proteins	NIDDK	Indiana University Indianapolis	6/20/2026	3/31/2031	Dog	\$840,284
K08HL179488	Cell surface localization of FVIII mimetic therapy	NHLBI	University of North Carolina Chapel Hill	7/1/2026	6/30/2031	Dog	\$166,924
75N93026C00013	To conduct investigational new drug (IND)-enabling studies of a pre-clinical candidate for the treatment of neurotropic alphaviruses.	NIAID	University of Tennessee	8/3/2026	7/31/2028	Dog	\$1,851,661
K99AI199993	Uncovering Resistance Mechanisms of the Anthelmintic Drugs Levamisole and Pyrantel	NIAID	Johns Hopkins University	8/4/2026	7/31/2028	Dog	\$125,000

BRAND-NEW AWARDS UNDER RFK



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	START DATE	END DATE	SPECIES	FUNDING
R44AI195119	Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infection	NIAID	Exavir Therapeutics, Inc.	8/4/2026	7/31/2029	Dog	\$998,034
R43DA066396	Development of cannabinoid receptor 2 agonists for opioid use disorder	NIDA	Longieva Therapeutics	8/15/2026	7/31/2027	Dog	\$399,989
R44CA302154	Novel Therapeutics to Treat HPV-Associated Cancers	NCI	Kovina Therapeutics, Inc.	8/14/2026	7/31/2028	Dog	\$1,143,891
R56AI193005	Advancing a novel oral anti-IAV therapeutic to the clinic	NIAID	Stanford University	8/11/2026	7/31/2027	Dog	\$1,265,732
R01HL175467	Immune landscape of mitral valve prolapse	NHLBI	Tufts University Boston	8/15/2026	5/31/2031	Dog	\$839,275
R01AR087066	Neuroimmune Contributions to Low Back Pain	NIAMS	Palo Alto Veterans Institute for Research	8/20/2026	6/30/2030	Dog	\$3,304,634
R44DK143820	IND-enabling studies of a USP30 inhibitor for acute kidney injury	NIDDK	Vincere Biosciences, Inc.	8/28/2026	5/31/2028	Dog	\$1,297,479
R21EY037150	Targeting TGFBeta-mediated IOP dysregulation in a large animal model of glaucoma	NEI	University of Wisconsin-Madison	8/1/2025	7/31/2027	Cat	\$439,016
R01NS140244	Determining the spatial limits and strengths of neurovascular coupling across layers of the cerebral cortex by using three-photon imaging of synapses, neurons and blood vessels	NINDS	University of Minnesota	8/1/2025	4/30/2030	Cat	\$972,220
R16DC024029	Development of AI-Assisted digital twin system for phonosurgery	NIDCD	Rochester Institute of Technology	9/1/2026	8/31/2030	Dog	\$145,613
U01AG103727	IND-enabling Development and First-in-Human Safety Exposure of MW073	NIA	Northwestern University	9/8/2026	8/31/2031	Dog	\$2,083,260
R01HL180465	Neural Control of Ventricular-Vascular Interactions During Exercise in Hypertension	NHLBI	Henry Ford Health + Michigan State University Health Sciences	9/5/2026	4/30/2031	Dog	\$773,282
R44AR086030	Pre-clinical development of a novel allosteric inhibitor of SRC kinase for spontaneous multi-joint osteoarthritis (OA) and OA-associated chronic pain	NIAMS	Reparris, Inc.	9/1/2026	2/28/2027	Dog	\$301,567
R44HL187127	A New and Disruptive Gene Based Therapy for Atrial Fibrillation	NHLBI	Inomagen Therapeutics, Inc	9/1/2026	5/31/2028	Dog	\$1,412,149

BRAND-NEW AWARDS UNDER RFK



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	START DATE	END DATE	SPECIES	FUNDING
R44HL186828	A Novel Water-Soluble, Orally-Active Peptide Therapeutic for Interstitial Lung Disease Derived from the Caveolin-1 Scaffolding Domain	NHLBI	Fibrotherapeutics, Inc.	9/5/2026	5/31/2027	Dog	\$920,624
R24AI201120	Production and Distribution of Filarial Research Reagents	NIAID	University of Georgia	9/1/2026	8/31/2031	Dog	\$1,023,862
R44NS149824	Development of a Non-Addictive Intranasal Nerve Block to Provide Rapid Acute Treatment for Headache Disorders	NINDS	Olfax, LLC	9/3/2026	8/31/2028	Dog	\$1,446,740

TOTAL: **\$92,439,920**

NEW RFK
MONEY,
EXISTING
AWARDS



Includes new NIH funding provided on or after February 13, 2025 — new budget periods, renewals, contract actions, and funded extensions — for dog and cat grants and contracts that originated before RFK became HHS Secretary.

GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
75N95024D00020	Safety evaluation and toxicology studies and related services for drug development	NCATS	IIT Research Institute	6/19/2030	Dog	\$34,740
R01DE031951	Engineered Nano-formulations for STING Activation	NIDCR	University of Michigan at Ann Arbor	2/28/2027	Dog	\$1,347,251
R01CA295558	Generating Synthetic Lethality in Glioblastoma with a First-In-Class Non-Muscle Myosin II Inhibitor	NCI	Mayo Clinic Jacksonville	12/31/2029	Dog	\$539,735
R44CA278026	Development of a Novel Resolvin-Based Therapy for Treatment of Pancreatic Cancer	NCI	Thetis Pharmaceuticals, LLC	5/31/2027	Dog	\$1,725,203
75N91022D00016	Preclinical toxicology of small molecule drugs developed for cancer and other indications	NCI	IIT Research Institute	9/25/2029	Dog	\$68,323
R44CA272064	Modulation of cancer induced immune suppression via inhibition of SCD1	NCI	Modulation Therapeutics, Inc.	8/31/2026	Dog	\$217,685
R01CA282475	Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers	NCI	University of California, San Francisco	8/31/2029	Dog	\$2,720,582
R44CA295214	Toxicology (IND-enabling) studies for a novel nerve imaging agent for prostate cancer	NCI	Manzanita Pharmaceuticals, Inc.	8/31/2026	Dog	\$1,090,970
R01CA258581	Transrectal Histotripsy for Focal Ablation of Prostate Cancer	NCI	University of Washington	8/31/2027	Dog	\$1,288,140
R44HD115509	Development of ADAM Air: A Non-Hormonal Vas Occlusive Contraceptive Device	NICHD	Contraline, Inc.	8/31/2027	Dog	\$1,906,493
75N91022C00010	Preclinical toxicology of large molecule drugs developed for cancer and other indications	NCI	IIT Research Institute	3/31/2029	Dog	\$570,021
R33EY036947	Translational studies to advance Filociclovir to IND submission for the treatment of adenoviral conjunctivitis and acute keratoconjunctivitis	NEI	Microbiotix	1/31/2028	Dog	\$669,859
UH3DA048743	Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.	NIDA	Kinoxis Therapeutics PTY LTD	5/31/2026	Dog	\$450,505
R01AG056998	Preclinical evaluation of tacrolimus in a canine model of Alzheimer's disease	NIA	University of California, Irvine	5/31/2027	Dog	\$1,812,048
R01EY006855	Models for Therapy of Hereditary Retinal Degeneration	NEI	University of Pennsylvania	12/31/2029	Dog	\$826,381
R01EY032478	Development of an IOP-lowering gene therapy treatment for glaucoma	NEI	Medical College of Wisconsin	5/31/2027	Dog	\$629,806
R01EY033049	Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retina	NEI	University of Pittsburgh	7/31/2026	Dog	\$614,243



NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
P30EY016665	Core Grant for Vision Research	NEI	University of Wisconsin-Madison	3/31/2028	Cat	\$1,150,700
P30EY014801	Miami Center for Vision Research	NEI	University of Miami School of Medicine	4/30/2028	Dog/Cat	\$741,328
K08EY031758	Virally expressed Stanniocalcin-1 for long-term intraocular pressure reduction	NEI	Mayo Clinic Rochester	8/31/2026	Dog/Cat	\$155,597
R01EY034901	Smart soft contact lenses for continuous 24-hour monitoring of intraocular pressure in glaucoma care	NEI	Purdue University	2/29/2028	Dog	\$1,109,083
R01HL171686	Novel Gene Therapy For Chronic Ischemic Heart Failure	NHLBI	University of Utah	12/31/2027	Dog	\$741,503
R01HL167672	Non-Pharmacologic Approach to Rhythm Control and Rate Control of Postoperative Atrial Fibrillation.	NHLBI	Case Western Reserve University	5/31/2028	Dog	\$805,000
R35HL161249	New and Disruptive Therapeutic Approaches to Target Fundamental Molecular Mechanisms Underlying Atrial Fibrillation	NHLBI	Northwestern University at Chicago	12/31/2028	Dog	\$2,192,768
R01HL160992	Role of Nucleoside-Diphosphate Kinase Signaling in Atrial Fibrillation	NHLBI	Baylor College of Medicine	1/31/2027	Dog	\$1,059,968
R01HL091541	Excitotoxicity and Mitochondrial Dysfunction in Circulatory Arrest- Brain Injury	NHLBI	Johns Hopkins University	4/30/2027	Dog	\$691,576
R01HL133080	Detyrosinated microtubules in cardiomyocyte mechanics	NHLBI	University of Pennsylvania	4/30/2030	Cat	\$516,209
R01HL163008	Central and Peripheral Regulation of Laryngeal Adduction	NHLBI	University of Florida	4/30/2027	Cat	\$686,054
R44HL135965	ErythroMer: Nanoscale BioSynthetic Red Cell Substitute	NHLBI	Kalocyte, Inc.	5/31/2027	Dog	\$995,470
R01HL032257	Surgical Treatment of Cardiac Arrhythmias	NHLBI	Washington University	7/31/2027	Dog	\$412,795
R44HL160424	Pharmacokinetic and Efficacy Studies of the Aerosolized PAR2 Antagonist, C781, for the Treatment of Asthma	NHLBI	Parmedics, Inc.	8/31/2026	Dog	\$792,665
R44HL174138	Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization	NHLBI	Nour Heart, Inc.	6/30/2027	Dog	\$1,923,922
R44HL174192	Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist	NHLBI	Shifa Biomedical Corporation	6/30/2027	Dog	\$1,150,186
R01AR071162	Noninvasive tools for assessing muscle structure and function	NIAMS	Northwestern University	5/31/2027	Cat	\$1,180,621

NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
R01HL135109	Targeting the Arrhythmogenic Sources of Human Atrial Fibrillation	NHLBI	Ohio State University	3/31/2027	Dog	\$1,290,223
R44HL142353	Aerosolized Vitamin A: Developing a Prevention for Hyperoxic Lung Injury and Bronchopulmonary Dysplasia, with Focus on Neonatal Lung Maturation	NHLBI	Advent Therapeutics, Inc.	2/28/2027	Dog	\$993,128
R01HL168117	Pathophysiological Significance of Atrial Fibrillation Electrogram Patterns	NHLBI	University of Miami School of Medicine	4/30/2028	Dog	\$1,332,248
R01HL166382	Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy	NHLBI	Versiti Wisconsin, Inc.	7/31/2027	Dog	\$1,419,414
R01HL177355	Targeted Gene Therapies for the Prevention of Prosthetic Bypass Graft Failure	NHLBI	Beth Israel Deaconess Medical Center	11/30/2029	Dog	\$710,174
R44HL174236	Development of a universal gene therapy for hemophilia A or B with or without inhibitors	NHLBI	Geneventiv Therapeutics, Inc.	3/31/2027	Dog	\$1,312,038
K08HL169904	Role of Endothelin-1 signaling in the development and progression of atrial fibrillation	NHLBI	Northwestern University at Chicago	8/31/2028	Dog	\$163,080
R44HL149496	Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.	NHLBI	Vasculonics, LLC	8/31/2027	Dog	\$1,276,514
R01HL168277	Cardiac Autonomic Activation In Atrial Fibrillation Triggers And Substrate	NHLBI	Methodist Hospital Research Institute	3/31/2028	Dog	\$1,589,922
R33HL177497	Immunocytokine therapy for immune modulation in hemophilia	NHLBI	Indiana University	11/30/2026	Dog	\$524,214
R01HL173557	Vascular-targeted Atheroprotective Gene therapies to Prevent Vein Graft Failure	NHLBI	Beth Israel Deaconess Medical Center	2/28/2028	Dog	\$1,465,665
R42HL149523	A New Small-Molecule Kinase Inhibitor for Airway Disease	NHLBI	Nupeak Therapeutics, Inc.	6/30/2027	Dog	\$1,019,816
R42HL156322	A New Anti-inflammatory Therapy for Ischemic Stroke	NHLBI	Cornovus Pharmaceuticals, Inc.	6/30/2027	Dog	\$1,109,152
F30HL173962	Loaded Fibrin-Specific Nanogels for Sepsis-Induced DIC	NHLBI	North Carolina State University Raleigh	9/29/2028	Dog	\$40,918
R42HL162392	Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis	NHLBI	Faknostics, LLC	7/31/2027	Dog	\$663,310
R01HL174056	Radiation Guided Ablation for Ventricular Tachycardia	NHLBI	University of Utah	5/31/2028	Dog	\$1,501,376
R01HL165238	Validation of Myocardial Oxygen Extraction Fraction Measurement with MRI	NHLBI	Washington University	6/30/2027	Dog	\$1,205,509

NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
U01AG076480	GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer’s Disease	NIA	Northwestern University at Chicago	5/31/2027	Dog	\$1,043,901
U01AG074950	Preclinical and early clinical development of a GABA-A a5 PAM	NIA	AgeneBio	8/31/2026	Dog	\$471,900
U01AG076481	Development of novel NLRP3 inflammasome inhibitors for intervening in Alzheimer’s disease	NIA	Virginia Commonwealth University	5/31/2027	Dog	\$2,996,117
U01AG074960	Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer’s Disease and Related Dementias	NIA	University of Georgia	5/31/2027	Dog	\$2,915,237
U01AG084549	Long-term, non-clinical toxicology for advancing CMS121 to Phase 2 trials for AD	NIA	Virogenics, Inc.	8/31/2027	Dog	\$2,907,979
75N93024D00035	Pre-clinical models of infectious diseases	NIAID	University of Georgia	7/14/2031	Dog/Cat	\$1,392,486
75N93020C00054	Covid-19. To develop small synthetic chemical molecules as broadly active antiviral for the treatment of viral infections.	NIAID	Stanford University	5/31/2030	Dog/Cat	\$4,694,959
R01AI177600	Mechanism of immune response to muscle-directed AAV gene transfer	NIAID	Indiana University	4/30/2028	Dog	\$1,518,754
R01AI182519	Genetics and Axenic Growth of tick-borne E. chaffeensis and A. phagocytophilum	NIAID	University of Missouri - Columbia	5/31/2029	Dog	\$1,073,482
R01AI155412	Optimization of Lead BKIs for Cryptosporidiosis Therapy	NIAID	University of Washington	12/31/2026	Dog	\$813,238
R01AI152417	Rocky Mountain Spotted Fever Vaccine Development	NIAID	University of Missouri - Columbia	8/31/2027	Dog	\$1,433,486
R44AI140708	A Vaccine for Lymphatic Filariasis, LFGuard™	NIAID	PAI Life Sciences, Inc.	11/30/2027	Dog	\$1,166,879
R01AI171971	Alteration of skin immune environment by sand fly saliva across progressive Leishmaniasis	NIAID	Ohio State University	6/30/2027	Dog	\$1,166,514
R01AI176543	Host Directed Orynotide for MDR Gram Negative Bacterial Infections	NIAID	University of Southern California	6/30/2028	Dog	\$2,033,088
R01AI176523	FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics	NIAID	University of Illinois at Urbana-Champaign	5/31/2028	Dog	\$1,955,594
R01AI165876	OspC and its role in defining host range and dissemination properties	NIAID	Virginia Commonwealth University	7/31/2026	Dog	\$527,756
R01AI152223	Targeted Prevention of Human Ehrlichiosis	NIAID	Ohio State University	7/31/2027	Dog	\$393,750

NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
T32AI007414	Parasitology and Vector Biology Training Program	NIAID	University of Wisconsin-Madison	6/30/2029	Cat	\$356,142
R01AI056189	B. thuringiensis crystal proteins as powerful next-generation anthelmintics	NIAID	University of Massachusetts Medical School	6/30/2029	Dog	\$1,455,484
R01AI179974	Engineered Mesenchymal Stromal Cells for Enhanced Immunosuppression	NIAID	Mayo Clinic Rochester	5/31/2029	Dog	\$1,614,894
R01AI160246	IND-Enabling Studies for Arenavirus Preclinical Candidate	NIAID	Arisan Therapeutics, Inc.	1/31/2027	Dog	\$915,066
R44AI179564	XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies	NIAID	Exavir Therapeutics, Inc.	7/31/2026	Dog	\$1,000,000
R01AI168242	Novel strategy to block Nabs for AAV gene delivery	NIAID	University of North Carolina Chapel Hill	2/28/2027	Dog	\$1,224,552
R41AI177149	Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase	NIAID	Lychee Bioscience, LLC	3/31/2027	Dog	\$299,985
R01AR040864	Dystrophin Replacement	NIAMS	University of Washington	6/30/2031	Dog	\$1,391,662
R01AR079572	Gene therapy for glycogen storage disease type III	NIAMS	Duke University	3/31/2027	Dog	\$1,240,772
R01AR080129	Role of Skeletal Muscle Lymphatics in Duchenne Muscular Dystrophy Regulation	NIAMS	Texas A&M University	4/30/2027	Dog	\$904,922
R01EB034660	Fluorescence image guided surgery, adjuvant PDT, and the immune response	NIBIB	Case Western Reserve University	4/30/2028	Dog	\$1,154,381
R01EB034011	Next Generation Cone Beam CT with Improved Contrast Resolution and Added Spectral Imaging Functionality	NIBIB	University of Wisconsin-Madison	4/30/2027	Dog	\$1,148,070
R01EB033354	3D-Nanoprinted Soft Robotic Microcatheters with Integrated Microfluidic Circuitry for Cerebrovascular Surgery	NIBIB	University of Maryland, College Park	4/30/2027	Dog	\$662,142
R01EB025741	Improved Detection of Prostate Cancer with Nanoparticle-based Ultrasound Contrast Agents Targeted to PSMA	NIBIB	Case Western Reserve University	1/31/2028	Dog	\$549,580
R01HD106916	Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I	NICHD	Children's Hospital of Orange County	2/29/2028	Dog	\$1,139,278

NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
R61HD114186	IND-enabling studies to develop triptonide into the first nonhormonal male pill	NICHD	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	1/31/2027	Dog	\$341,600
75N94020D00003	Biological testing facility IDIQ	NICHD	SRI International	11/30/2027	Dog	\$3,664,893
UH3DA048338	A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder	NIDA	Drug Delivery Company, LLC	4/30/2027	Dog	\$5,423,906
R44DA056272	A Novel Reversal Agent for Treatment of Overdose from the Combination of Fentanyl and Xylazine	NIDA	Clear Scientific, LLC	7/31/2026	Dog	\$1,536,796
R44DA061722	NX90: A Treatment for Overdose Caused by High Potency Opioids	NIDA	Serodopa Therapeutics	8/31/2026	Dog	\$1,407,382
T32DC011499	Training in Auditory and Vestibular Neuroscience	NIDCD	University of Pittsburgh	6/30/2027	Cat	\$419,155
R01DC019114	Optimizing a patient-specific regenerative larynx implant for restoration of voice	NIDCD	Mayo Clinic Arizona	8/31/2026	Dog	\$628,870
R01DC009435	The Relationship Between Vortices, Acoustics, and Vibration in Vocal Fold Asymmetries	NIDCD	University of Cincinnati	3/31/2027	Dog	\$629,761
R01DE030413	Dose analysis for translating animal based vibrational force study for accelerating orthodontic tooth movement to clinic	NIDCR	Purdue University	3/31/2027	Dog	\$831,513
R01DE031213	Biofilm Spatial Structure in the Transition from Health to Periodontal Disease	NIDCR	State University of New York at Albany	7/31/2027	Dog	\$461,884
ZIAAI001017	Parasite Surface Antigens and Immunity	NIAID	Intramural		Cat	\$584,442
ZIADE000699	Cell surface proteolysis in development, tissue repair, and malignancy	NIDCR	Intramural		Dog	\$1,430,453
R44DK141341	Development of an Oral Pill to Mimic the Effects of Gastric Bypass Surgery	NIDDK	Syntis Bio, Inc.	8/31/2027	Dog	\$1,833,064
R01DK132082	Deglutitive and airway protective functions of proximal/ striated muscle esophagus in health and disease	NIDDK	Medical College of Wisconsin	2/28/2027	Cat	\$469,026
R01DK136505	Characterization of Hypogastric Afferent Pathway Involved in Urinary Bladder Function and Dysfunction	NIDDK	University of Pittsburgh	6/30/2027	Cat	\$397,500
R44DK116460	Development of TP-317 in Ulcerative Colitis	NIDDK	Thetis Pharmaceuticals, LLC	2/28/2027	Dog	\$999,696
U54DK106829	Stem Cell and Transplantation Biology	NIDDK	Fred Hutchinson Cancer Center	7/31/2026	Dog	\$1,755,079

NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
R01DK018243	Gluconeogenesis and Glycogenolysis - Role and Regulation	NIDDK	Vanderbilt University	5/31/2027	Dog	\$1,355,303
R01DK063973	Gene Transfer and NMR Studies in Alpha-Mannosidosis Brain	NIDDK	Children's Hospital of Philadelphia	7/31/2027	Cat	\$739,053
R01DK029867	Quantitation of Factors Regulating Glucose Tolerance	NIDDK	Cedars-Sinai Medical Center	3/31/2027	Dog	\$584,500
R01DK128597	Urolithin A nanoparticle therapy for acute kidney injury	NIDDK	University of Alabama in Tuscaloosa	3/31/2027	Dog	\$323,152
F31DK142297	The Impact of Morning Insulin Delivery on Hepatic Glucose Metabolism Later in the Day	NIDDK	Vanderbilt University	12/31/2026	Dog	\$34,898
R01DK106364	On the regulation of hepatic glucose metabolism during insulin-induced hypoglycemia	NIDDK	University of Cincinnati	12/31/2027	Dog	\$605,994
R01DK072381	Kidney Injury Molecule-1 in Epithelial Repair	NIDDK	Brigham and Women's Hospital	6/30/2027	Dog	\$527,738
R01NS138410	Mitigation of Cerebral Infarct Growth in Acute Ischemic Stroke Using a Novel Blood Substitute	NINDS	University of Chicago	7/31/2029	Dog	\$596,070
R01NS090634	Whole body single AAV microgene in canine DMD	NINDS	University of Missouri - Columbia	4/30/2030	Dog	\$1,183,177
R44NS120360	Development of N-tert-(butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating CLN1 Batten Disease	NINDS	Circumvent Pharmaceuticals	6/30/2027	Dog	\$2,464,063
R01NS110550	Limb coordination during locomotion before and after spinal cord injury	NINDS	Drexel University/GA Tech	7/31/2030	Cat	\$1,076,330
R01NS121028	Electrodes for selective stimulation of the lateral spinal cord to restore sensation after lower-limb amputation	NINDS	University of Pittsburgh	2/28/2027	Cat	\$1,171,098
R01NS131416	CRISPR editing therapy for Duchenne muscular dystrophy	NINDS	University of Missouri - Columbia	6/30/2028	Dog	\$1,100,939
R21NS140942	Effects of on-demand and early neuromodulation interventions on bladder function after spinal cord injury	NINDS	University of Pittsburgh	11/30/2026	Cat	\$198,750
R01NS092882	Reliable Seizure Prediction Using Physiological Signals and Machine Learning	NINDS	Mayo Clinic Rochester	5/31/2027	Dog	\$1,076,652
U01NS128612	An Ecosystem of Technology and Protocols for Adaptive Neuromodulation Research in Humans	NINDS	Mayo Clinic Rochester	5/31/2027	Dog	\$2,022,441
R00HL164962	Tachycardia-induced Metabolic Remodeling Drives Cardiac Dysfunction	NHLBI	UT Southwestern Medical Center	1/31/2029	Dog	\$249,000

NEW RFK MONEY, EXISTING AWARDS



GRANT NUMBER	TITLE	AWARDING SUBAGENCY	AWARDEE	EXPIRATION DATE	SPECIES	FUNDING
R44HL172325	Lazzaro Medical Scaffold System for improved treatment of tracheobronchomalacia	NHLBI	Lazzaro Medical, Inc.	5/31/2026	Dog	\$1,104,123
R44HL166018	Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia	NHLBI	Reneurogen, LLC	5/31/2026	Dog	\$50,000
R01NS124820	The organization of spinal neurons following spinal cord injury	NINDS	Temple University	1/31/2027	Cat	\$655,659
R01HL134321	Intraosseous delivery of lentiviral vectors for hemophilia A gene therapy	NHLBI	Seattle Children's Hospital	5/31/2030	Dog	\$822,265
R37NS135820	Neuromodulation of motoneuronal processing of dynamic synaptic inputs	NINDS	Northwestern University	3/31/2028	Cat	\$737,200

TOTAL: **\$135,489,606**

METHODOLOGY

What we track:


This investigation covers NIH funding actions from February 13, 2025 — the date Robert F. Kennedy Jr. took office as HHS Secretary — through September 8, 2026. “New spending” refers to taxpayer funds awarded by NIH for grants and contracts supporting dog and/or cat experiments during this period. This analysis includes funding provided through entirely new awards, new grant budget periods, competitive renewals, contract actions, and funded extensions. An award may have originated before February 13, 2025, but only qualifying funding actions occurring on or after that date are included.

How we find it:

White Coat Waste maintains a dataset of NIH grants and contracts confirmed to support dog and/or cat experiments, as well as awards classified as likely to support such experiments. For likely awards, available project descriptions, award records, publications, and related documentation indicate that the specific award involves dog and/or cat use, but award-level confirmation is still pending. The headline total includes both confirmed and likely awards. White Coat Waste’s proprietary automated tracking system monitors NIH RePORTER and USAspending for new awards containing dog- and cat-related terms as well as funding or administrative updates to awards already being tracked.

How we verify it:

Investigators then review the results using project descriptions, award terms, publications, linked resources, and other publicly available records. For every newly awarded grant or contract confirmed or likely to involve dogs or cats, White Coat Waste then submits a Freedom of Information Act request to obtain the underlying records and independently verify the species and procedures identified through the initial award review. As additional information becomes available, awards are reclassified when appropriate and the funding total is updated accordingly.



ABOUT WHITE COAT WASTE



Founded in 2011 by Anthony Bellotti — a former lab worker turned Republican strategist — White Coat Waste is a bipartisan taxpayer watchdog on a mission to expose and close the U.S. government's \$20 billion animal experimentation business.

White Coat Waste was the first to uncover Dr. Fauci's beagle experiments, the first to expose U.S. taxpayer funding for the Wuhan Institute of Virology, the first to reveal transgender mice experiments, and the first to expose USDA's kitten cannibalism experiments — and led the campaign that shut down the federal government's largest cat laboratory.

White Coat Waste is a 501(c)(3) nonprofit organization. Our investigations and campaigns have been featured in The Wall Street Journal, Fox News, USA Today, The Economist, and more.



In recent years, a new kind of group has played a pivotal role in transforming animal testing into a **right-wing cause**.

The White Coat Waste Project, started by a conservative activist... has spearheaded that effort, calling for an **end to animal testing** programs across federal agencies."

The New York Times

July 3, 2025

About the investigator

Kailey Mauro is the lead author of *MAHA Betrayed*. She manages White Coat Waste's investigations using FOIA, open records requests, and federal spending databases to follow the money and build a documentary record on taxpayer-funded animal experiments.

kailey
mauro



WHITE COAT WASTE

/WHITECOATWASTE

WHITECOATWASTE.ORG

@WHITECOATWASTE